SAR445399 Phase 2 Bronchiectasis Trial, Ages 18-80
Summary
This is a Phase 2 randomized, double-blind, placebo-controlled clinical trial (NCT07547436) evaluating SAR445399 in adults aged 18 to 80 years with non-cystic fibrosis bronchiectasis. The study will measure reduction in mucus plug score at 24 weeks of treatment compared with placebo. Trial status is listed as active as of April 23, 2026.
“This is a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score at 24 weeks of treatment with SAR445399 compared with placebo in adult participants aged 18 to 80 years with non-cystic fibrosis bronchiectasis (NCFB).”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
Clinical trial NCT07547436 is a Phase 2 randomized, double-blind, placebo-controlled study sponsored under NIH ClinicalTrials.gov registration. It evaluates SAR445399 for reduction in mucus plug score over 24 weeks in adult participants aged 18-80 with non-cystic fibrosis bronchiectasis.
Pharmaceutical companies, clinical investigators, and healthcare providers involved in respiratory or bronchiectasis research should note this trial's design and endpoints. The study represents a formal clinical development activity registered in the public NIH database, which may be relevant to competitive landscape assessments or patient referral considerations.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis
Phase 2 NCT07547436 Kind: PHASE2 Apr 23, 2026
Abstract
This is a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score at 24 weeks of treatment with SAR445399 compared with placebo in adult participants aged 18 to 80 years with non-cystic fibrosis bronchiectasis (NCFB).
Conditions: Non-cystic Fibrosis Bronchiectasis
Interventions: SAR445399, Placebo
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.